# NervGen Pharma (NGEN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/NGEN
## Company Profile
- Ticker: NGEN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
- Tags: CNS
## Stock Data
- Close: 1.68 USD
- Market cap: 212406272 USD
- Last updated: 2026-08-05
## Business Overview
### Neuroreparative Therapeutics Company
NervGen Pharma develops first-in-class neuroreparative therapies for spinal cord injury and other neurological trauma and disease. Its objective is to promote nervous-system repair and improve function, independence, and quality of life.
### NVG-291 Mechanism and Positioning
Lead candidate NVG-291 is a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTPσ pathway. The program has received FDA Fast Track designation and EMA Orphan Drug designation for spinal cord injury.
### Registrational Path in Chronic Tetraplegia
Following an End-of-Phase 2 meeting, NervGen reached alignment with the FDA on key parameters for the RESTORE registrational study of NVG-291 in chronic tetraplegia.
### Clinical Evidence in Spinal Cord Injury
The CONNECT SCI program evaluates whether NVG-291 can improve neurological and functional outcomes in people living with spinal cord injury. Biomarker, motor-function, and gait analyses from this work inform the design and endpoints of the registrational program.
### Expansion Beyond Spinal Cord Injury
Because CSPG-PTPσ signaling is implicated in inhibited nervous-system repair, NervGen is evaluating additional neurological trauma and disease indications for NVG-291. The company plans to prioritize opportunities based on biological rationale, development feasibility, and available resources.
## Why The Stock Is Moving

As of Aug 5, 2026, NGEN closed up 1.20% at $1.68. No new same-company headline was identified in the current news window.

## Future Catalysts

- Site activation has begun for the RESTORE registrational study, which was expected to start in mid-2026.
- Results from an independent, blinded biomechanical gait analysis in the Phase 1b/2a CONNECT SCI study were expected in the second quarter of 2026.
- NervGen expected to disclose a prioritization framework in mid-2026 for expanding NVG-291 into additional neurological trauma and disease indications.

## Recent News
- 2026-05-26 11:15 EST — [NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study](https://biopharmsignal.com/news/NGEN/nervgen-announces-positive-independent-blinded-biomechanical-gait-analyses-demon-0bf3b1bf) — Source: NervGen Pharma
- 2026-05-22 03:27 EST — [NervGen Announces Pricing of US$60.0 Million Public Offering of Securities](https://biopharmsignal.com/news/NGEN/nervgen-announces-pricing-of-us-60-0-million-public-offering-of-securities-c0024b9c) — Source: NervGen Pharma
- 2026-05-21 20:01 EST — [NervGen Announces Proposed Public Offering of Securities](https://biopharmsignal.com/news/NGEN/nervgen-announces-proposed-public-offering-of-securities-fc0d7421) — Source: NervGen Pharma
- 2026-05-18 11:15 EST — [NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/NGEN/nervgen-reports-first-quarter-2026-financial-results-and-provides-business-updat-d7cfb0d6) — Source: NervGen Pharma
- 2026-04-27 11:30 EST — [NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer](https://biopharmsignal.com/news/NGEN/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as--fd2a832c) — Source: NervGen Pharma